REReza Eghdam-Zamiri

Reza Eghdam-Zamiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reza Eghdam-Zamiri has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Abbas Karimi

    Department of Molecular Medicine, Faculty of Advanced Medical Sciences Tabriz University of Medical Sciences Tabriz Iran

    1 shared publication
  • Ebrahim Esmati

    Department of Radiation Oncology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Farhad Jeddi

    Department of Genetics and Pathology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

    1 shared publication
  • Maryam Vaezi

    Department of Obstetrics and Gynecology, Fellowship of Gynecology Oncology, Alzahra Teaching Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    1 shared publication
  • Masoumeh Bakhshandeh

    Obstetric and Oncology Department, School of Medicine, Women’s Reproductive Health Research Center, Clinical Research Institute, Alzahra Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    1 shared publication
  • Masoumeh Parvizi

    Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

    1 shared publication

Latest Publications

  • Open Access

    The role and diagnostic value of deregulated miRNAs in cervical cancer

    by Masoumeh Parvizi, Maryam Vaezi, Farhad Jeddi, Masoumeh Bakhshandeh, Reza Eghdam-Zamiri, Noushin Mobaraki-Asl, Ebrahim Esmati, Abbas Karimi

    Cervical cancer (CC) remains a significant global health concern, particularly affecting women in low-income countries. Despite advancements in screening programs, CC continues to pose a substantial mortality risk, highlighting the need to explore diagnostic and treatment modalities. This review focuses on the role of deregulated microRNAs (miRNAs) in CC development, emphasizing their potential as biomarkers for early detection and prognosis in body fluids. miRNAs have emerged as critical regulators of key cellular processes, including proliferation, migration, invasion, and apoptosis, and their dysregulation is closely linked to CC progression. Upregulated miRNAs such as miR-146b-3p, miR-1908, and miR-21 promote CC progression by targeting tumor suppressor genes, while downregulated miRNAs like miR-23-3p and miR-4262 are associated with reduced tumor aggressiveness. miRNAs also hold significant promise as non-invasive prognostic biomarkers. Their expression levels correlate with clinical outcomes, including tumor stage, metastasis, and overall survival, making them valuable tools for risk stratification and personalized treatment strategies. Liquid biopsies, which detect circulating miRNAs in bodily fluids, offer a minimally invasive approach to monitor tumor dynamics and predict patient outcomes. Furthermore, exosomal miRNAs are emerging as promising diagnostic and prognostic tools for CC. Advanced diagnostic technologies and bioinformatics tools are anticipated to enhance the identification of evident miRNA biomarkers in the clinical settings. Standardized protocols for sample collection and analysis will improve the reproducibility of miRNA studies, while a deeper understanding of miRNA biology may unlock their potential as therapeutic targets. In conclusion, this review consolidates current research on deregulated miRNAs in CC, highlighting their diagnostic and prognostic significance. The findings underscore the potential of miRNAs to revolutionize CC management through innovative diagnostic and therapeutic strategies.